相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)
Jing Luan et al.
JOURNAL OF DRUG TARGETING (2020)
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Junko Murai et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Sara Pusceddu et al.
CANCERS (2019)
Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer
Man Li et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Awa Sarr et al.
SCIENTIFIC REPORTS (2019)
miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis
Madhav Madurantakam Royam et al.
CANCERS (2019)
TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1
Guillem Lambies et al.
CANCER RESEARCH (2019)
Enhancing responsiveness of pancreatic Cheek for cancer cells to gemcitabine treatment under updates hypoxia by heme oxygenase-1 inhibition
Maher Y. Abdalla et al.
TRANSLATIONAL RESEARCH (2019)
Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition
Rita T. Lawlor et al.
CANCERS (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis
Q. L. Han et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2018)
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial
Talar Tatarian et al.
ANNALS OF SURGERY (2018)
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
Rosemary Young et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
N. O. Elander et al.
BRITISH JOURNAL OF CANCER (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Tumor-Stroma IL1 beta-IRAK4 Feedforward Circuitry DrivesTumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
Daoxiang Zhang et al.
CANCER RESEARCH (2018)
MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy
Limin Huang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome Editing
Raffaella Belvedere et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang et al.
INVESTIGATIONAL NEW DRUGS (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Guangbing Xiong et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review
Ezzeddine Chouat et al.
PANCREATOLOGY (2018)
EMT: Mechanisms and therapeutic implications
Mohini Singh et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
Sarah P. Blagden et al.
BRITISH JOURNAL OF CANCER (2018)
Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
Etienne Giroux-Leprieur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
Zhongyi Guo et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
Jie Cao et al.
MOLECULAR CANCER (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells
Ita Novita Sari et al.
CELLS (2018)
Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides
Richard Daifuku et al.
PHARMACEUTICALS (2018)
A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study
Sukhwinder Kaur et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Equilibrative nucleoside transportersA review
Rebba C. Boswell-Casteel et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2017)
The role of stromal cancer-associated fibroblasts in pancreatic cancer
Dagny von Ahrens et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial)
Ken-ichi Okada et al.
ONCOLOGY (2017)
Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy
Marek Sierzega et al.
PANCREAS (2017)
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Patricia Dauer et al.
PANCREATOLOGY (2017)
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine
Toru Aoyama et al.
ONCOLOGY LETTERS (2017)
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
Ali McBride et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
Renata D. Peixoto et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Surendra K. Shukla et al.
CANCER CELL (2017)
The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer
Guangbing Xiong et al.
CANCER LETTERS (2017)
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial
Jean-Baptiste Bachet et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer
Prince Saforo Amponsah et al.
CANCER LETTERS (2017)
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
N. T. E. Bird et al.
BRITISH JOURNAL OF SURGERY (2017)
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
Jacob Elebro et al.
ACTA ONCOLOGICA (2016)
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
Knut J. Labori et al.
ACTA ONCOLOGICA (2016)
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer
Zhi-Guo Ren et al.
ONCOLOGY REPORTS (2016)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
被撤回的出版物: Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis (Retracted article. See vol. 89, pg. 149, 2022)
Chenggang Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer
Pei Fan et al.
CANCER LETTERS (2016)
GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-7-5p in pancreatic cancer
Jiangning Gu et al.
CANCER LETTERS (2016)
Key role of pancreatic stellate cells in pancreatic cancer
Srinivasa P. Pothula et al.
CANCER LETTERS (2016)
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Lucy Ireland et al.
CANCER RESEARCH (2016)
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
A. Orlandi et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer
Yang Liu et al.
TUMOR BIOLOGY (2016)
Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
Xuefei Tian et al.
ONCOLOGY LETTERS (2016)
Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice
Roman Maresch et al.
NATURE COMMUNICATIONS (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival
Daniel Delitto et al.
BMC CANCER (2015)
Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer
J. A. Galvan et al.
BRITISH JOURNAL OF CANCER (2015)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumourchemoresistance
Camille Duluc et al.
EMBO MOLECULAR MEDICINE (2015)
Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma
Ilona Kohler et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2
Takuya Shimada et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
Kentaro Minami et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment
Ken Ohmine et al.
MOLECULAR PHARMACEUTICS (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer
Feng Cao et al.
ONCOLOGY REPORTS (2015)
Pancreatic cancer: The microenvironment needs attention too!
M. V. Apte et al.
PANCREATOLOGY (2015)
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
Nicolas Skrypek et al.
ONCOTARGET (2015)
Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
Hui Zhang et al.
ONCOTARGET (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response
Alexandre Marechal et al.
CELL RESEARCH (2015)
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
Congfei Wang et al.
ONCOLOGY REPORTS (2015)
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer A dual-institutional follow-up with the RTOG 9704 trial
Florencia McAllister et al.
CANCER BIOLOGY & THERAPY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
Magdalena Slusarczyk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Acquired and intrinsic resistance in cancer immunotherapy
Sander Kelderman et al.
MOLECULAR ONCOLOGY (2014)
DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets
Corynn Kasap et al.
NATURE CHEMICAL BIOLOGY (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
D. Li et al.
PANCREATOLOGY (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Stina Nordh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Beatrice Mohelnikova-Duchonova et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
F. E. Stuurman et al.
INVESTIGATIONAL NEW DRUGS (2013)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
N. Skrypek et al.
ONCOGENE (2013)
Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner
S. Perez-Torras et al.
CELL DEATH & DISEASE (2013)
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy
Mun Hui et al.
BREAST CANCER RESEARCH (2013)
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Yuriko Saiki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Early diagnosis of pancreatic cancer: challenges and new developments
Sukhwinder Kaur et al.
BIOMARKERS IN MEDICINE (2012)
Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance
Feng-Ting Huang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells
Yangzom D. Bhutia et al.
CANCER RESEARCH (2011)
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
Andries M. Bergman et al.
INVESTIGATIONAL NEW DRUGS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression
Ke Tang et al.
ONCOLOGY REPORTS (2011)
Role of microRNA in anticancer drug resistance
Tongsen Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Naotake Funamizu et al.
ONCOLOGY REPORTS (2010)
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Christina L. Costantino et al.
CANCER RESEARCH (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Suzie J. Scales et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug
Weidong Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Shin Nakahira et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate
P Chen et al.
ANTI-CANCER DRUGS (2006)
Hedgehog signalling in prostate regeneration, neoplasia and metastasis
SS Karhadkar et al.
NATURE (2004)
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
DN Watkins et al.
NATURE (2003)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)
分享论文
